InvestorsHub Logo
icon url

prototype_101

08/16/21 4:38 PM

#76848 RE: WhiteSahara #76846

We expect that we will incur approximately $816,000 of expenditures per month over the next 12 months. Our current cash position enables us to finance our operations through November 2022. On July 2, 2021, the Company filed a $100,000,000 universal shelf registration statement with the U.S. Securities and Exchange Commission which became effective on July 9, 2021

Ok, so basically funded for all of 2021 and 2022, this will be plenty of time for the mass commercialization to take root and LWLG turn cash flow positive
icon url

frobinso

08/16/21 4:45 PM

#76851 RE: WhiteSahara #76846

It seems that last sale to conclude the purchase agreements garnered about 3.69 per share, so it was concluded prior to being able to take full advantage of the significant rise in shareprice that subsequently followed, as I understand the 10-Q.

I have seen this occur with many small companies a majority of the time, including most recently with my investment in MVIS. So LWLG did not really get to maximize the value on the two final purchase agreements.

Companies operate quite conservatively, and at the conclusion of the purchase agreement who would have foreseen the impact of Lebby's shot across the bow to the industry as they took notice of the ASM presentation.

That potential will still define the company and it's valuation going forward.

I still feel the best path forward would be to engage with a big name company at the point of mass commercialization to navigate the ramp-up, and any financing activities. Dr. Lebby has the industry leadership and credibility to pull this off, with future financing to occur at much higher shareprice levels.